In vitro diagnosis of delayed-type drug hypersensitivity: Mechanistic aspects and unmet needs

Immunology and Allergy Clinics of North America

Volumn 34, Issue 3, 2014, Pages 691-705

  Naisbitt, Dean J ^a   Nattrass, Ryan G ^a   Ogese, Monday O ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Altered peptide repertoire hypothesis; Delayed type drug hypersensitivity; Hapten hypothesis; PI hypothesis; T lymphocytes

Indexed keywords

BETA LACTAM ANTIBIOTIC; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; HAPTEN; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; PEPTIDE; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

CELL CLONING; CYSTIC FIBROSIS; DELAYED HYPERSENSITIVITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO STUDY; INTRACELLULAR CYTOKINE STAINING; LABORATORY TEST; LYMPHOCYTE TRANSFORMATION TEST; MULTIPLEX ASSAY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SENSITIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; DRUG HYPERSENSITIVITY; HYPERSENSITIVITY, DELAYED; IMMUNOASSAY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

DRUG HYPERSENSITIVITY; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOASSAY; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTE SUBSETS;

EID: 84904036707     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.04.009     Document Type: Review

References (85)

1. Pichler W.J., Naisbitt D.J., Park B.K. Immune pathomechanism of drug hypersensitivity reactions. JAllergy Clin Immunol 2011, 127(Suppl 3):S74-S81.
2. Clinical aspects of immunology 1963, Blackwell, Oxford (United Kingdom). P.G. Gell, R.R. Coombs (Eds.).
3. Pichler W.J. Delayed drug hypersensitivity reactions. Ann Intern Med 2003, 139(8):683-693.
4. Monshi M.M., Faulkner L., Gibson A., et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological B*57(2):727-739.
5. Spanou Z., Keller M., Britschgi M., et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. JAm Soc Nephrol 2006, 17(10):2919-2927.
6. Uetrecht J., Naisbitt D.J. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013, 65(2):779-808.
7. Illing P.T., Vivian J.P., Purcell A.W., et al. Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol 2013, 25(1):81-89.
8. Pichler W.J. Consequences of drug binding to immune receptors: immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. Dermatologica Sinica 2013, 31(4):181-190.
9. Ashby J., Basketter D.A., Paton D., et al. Structure activity relationships in skin sensitization using the murine local lymph node assay. Toxicology 1995, 103(3):177-194.
10. Landsteiner K., Jacobs J. Studies on the sensitization of animals with simple chemical compounds. JExp Med 1935, 61:643-656.
11. Martin S.F., Esser P.R., Schmucker S., et al. T-cell recognition of chemicals, protein allergens and drugs: towards the development of invitro assays. Cell Mol Life Sci 2010, 67(24):4171-4184.
12. Gerberick G.F., Troutman J.A., Foertsch L.M., et al. Investigation of peptide reactivity of pro-hapten skin sensitizers using a peroxidase-peroxide oxidation system. Toxicol Sci 2009, 112(1):164-174.
13. Gerberick F., Aleksic M., Basketter D., et al. Chemical reactivity measurement and the predictive identification of skin sensitisers. The report and recommendations of ECVAM Workshop 64. Altern Lab Anim 2008, 36(2):215-242.
14. Chang C., Mahmood M.M., Teuber S.S., et al. Overview of penicillin allergy. Clin Rev Allergy Immunol 2012, 43(1-2):84-97.
15. Pullen H., Wright N., Murdock J.M. Hypersensitivity to the penicillins. Lancet 1968, 1(7551):1090.
16. Batchelor F.R., Dewdney J.M., Gazzard D. Penicillin allergy: the formation of the penicilloyl determinant. Nature 1965, 206:362-364.
17. Levine B.B., Ovary Z. Studies on the mechanism of the formation of the penicillin antigen. III. The N-(D-alpha-benzylpenicilloyl) group as an antigenic determinant responsible for hypersensitivity to penicillin G. JExp Med 1961, 114:875-904.
18. Levine B.B. Studies on the mechanism of the formation of the penicillin antigen. I.Delayed allergic cross-reactions among penicillin G and its degradation products. JExp Med 1960, 112:1131-1156.
19. El-Ghaiesh S., Monshi M.M., Whitaker P., et al. Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis. JPharmacol Exp Ther 2012, 341(3):597-610.
20. Whitaker P., Meng X., Lavergne S.N., et al. Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. JImmunol 2011, 187(1):200-211.
21. Meng X., Jenkins R.E., Berry N., et al. Direct evidence for the formation of diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillenic acid in patients. JPharmacol Exp Ther 2011, 338:841-849.
22. Castrejon J.L., Lavergne S.N., El-Sheikh A., et al. Metabolic and chemical origins of cross-reactive immunological reactions to arylamine benzenesulfonamides: T-cell responses to hydroxylamine and nitroso derivatives. Chem Res Toxicol 2010, 23(1):184-192.
23. Callan H.E., Jenkins R.E., Maggs J.L., et al. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol 2009, 22(5):937-948.
24. Sanderson J.P., Naisbitt D.J., Farrell J., et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. JImmunol 2007, 178(9):5533-5542.
25. Naisbitt D.J., Farrell J., Gordon S.F., et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002, 62(3):628-637.
26. Megherbi R., Kiorpelidou E., Foster B., et al. Role of protein haptenation in triggering maturation events in the dendritic cell surrogate cell line THP-1. Toxicol Appl Pharmacol 2009, 238(2):120-132.
27. Pickard C., Louafi F., McGuire C., et al. The cutaneous B*576-7584.
28. Pickard C., Smith A.M., Cooper H., et al. Investigation of mechanisms underlying the T-cell response to the hapten 2,4-dinitrochlorobenzene. JInvest Dermatol 2007, 127(3):630-637.
29. Jenkins R.E., Meng X., Elliott V.L., et al. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA invitro and invivo. Proteomics Clin Appl 2009, 3(6):720-729.
30. Hertl M., Geisel J., Boecker C., et al. Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993, 128:619-626.
31. Sachs B., Erdmann S., Malte Baron J., et al. Determination of interleukin-5 secretion from drug-specific activated exvivo peripheral blood mononuclear cells as a test system for the invitro detection of drug sensitization. Clin Exp Allergy 2002, 32(5):736-744.
32. Rozieres A., Hennino A., Rodet K., et al. Detection and quantification of drug-specific T cells in penicillin allergy. Allergy 2009, 64(4):534-542.
33. Beeler A., Engler O., Gerber B.O., et al. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. JAllergy Clin Immunol 2006, 117(2):455-462.
34. Brugnolo F., Annunziato F., Sampognaro S., et al. Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions. JImmunol 1999, 163(2):1053-1059.
35. Mauri-Hellweg D., Zanni M., Frei E., et al. Cross-reactivity of T cell lines and clones to B*57(3):1071-1079.
36. Brander C., Mauri-Hellweg D., Bettens F., et al. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. JImmunol 1995, 155(5):2670-2678.
37. Nhim C., Delluc S., Halgand F., et al. Identification and frequency of circulating CD4(+) T lymphocytes specific to benzylpenicillin in healthy donors. Allergy 2013, 68(7):899-905.
38. Padovan E., Mauri-Hellweg D., Pichler W.J., et al. Tcell recognition of penicillin G: structural features determining antigenic specificity. Eur J Immunol 1996, 26:42-48.
39. Manchanda T., Hess D., Dale L., et al. Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol Pharmacol 2002, 62(5):1011-1026.
40. Naisbitt D.J., Gordon S.F., Pirmohamed M., et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation invivo. Br J Pharmacol 2001, 133(2):295-305.
41. Farrell J., Naisbitt D.J., Drummond N.S., et al. Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. JPharmacol Exp Ther 2003, 306(1):229-237.
42. Faulkner L., Martinsson K., Castelazo A.S., et al. The development of invitro culture methods to characterize primary T cell responses to drugs. Toxicol Sci 2012, 127:150-158.
43. Engler O.B., Strasser I., Naisbitt D.J., et al. Achemically inert drug can stimulate Tcells invitro by their T cell receptor in non-sensitised individuals. Toxicology 2004, 197(1):47-56.
44. Castrejon J.L., Berry N., El-Ghaiesh S., et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. JAllergy Clin Immunol 2010, 125(2):411-418.e4.
45. Schnyder B., Burkhart C., Schnyder-Frutig K., et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. JImmunol 2000, 164(12):6647-6654.
46. Nassif A., Bensussan A., Boumsell L., et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. JAllergy Clin Immunol 2004, 114(5):1209-1215.
47. Elsheikh A., Lavergne S.N., Castrejon J.L., et al. Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism. JImmunol 2010, 185(11):6448-6460.
48. Elsheikh A., Castrejon L., Lavergne S.N., et al. Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. JAllergy Clin Immunol 2011, 127(6):1543-1551.e3.
49. Lavergne S.N., Whitaker P., Peckham D., et al. Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis. Chem Res Toxicol 2010, 23(6):1009-1011.
50. Yun J., Adam J., Yerly D., et al. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy 2012, 67:1338-1346.
51. Mauri-Hellweg D., Bettens F., Mauri D., et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. JImmunol 1995, 155(1):462-472.
52. Burkhart C., von Greyerz S., Depta J.P., et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 2001, 132(3):623-630.
53. Zanni M.P., von Greyerz S., Schnyder B., et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta Tlymphocytes. JClin Invest 1998, 102(8):1591-1598.
54. Schnyder B., Mauri-Hellweg D., Zanni M., et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. JClin Invest 1997, 100(1):136-141.
55. Wuillemin N., Adam J., Fontana S., et al. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. JImmunol 2013, 190(10):4956-4964.
56. Keller M., Lerch M., B*57-268.
57. Mallal S., Phillips E., Carosi G., et al. HLA-B*5701 screening for hypersensitivity to aB*579.
58. Illing P.T., Vivian J.P., Dudek N.L., et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012, 486(7404):554-558.
59. Ostrov D.A., Grant B.J., Pompeu Y.A., et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012, 109(25):9959-9964.
60. Norcross M.A., Luo S., Lu L., et al. AB*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012, 26(11):F21-F29.
61. Chessman D., Kostenko L., Lethborg T., et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008, 28(6):822-832.
62. Nyfeler B., Pichler W.J. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997, 27:175-181.
63. Pichler W.J., Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004, 59(8):809-820.
64. Wu Y., Farrell J., Pirmohamed M., et al. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. JAllergy Clin Immunol 2007, 119(4):973-981.
65. Wu Y., Sanderson J.P., Farrell J., et al. Activation of T cells by carbamazepine and carbamazepine metabolites. JAllergy Clin Immunol 2006, 118(1):233-241.
66. Naisbitt D.J., Britschgi M., Wong G., et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003, 63(3):732-741.
67. Naisbitt D.J., Farrell J., Wong G., et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. JAllergy Clin Immunol 2003, 111(6):1393-1403.
68. Porebski G., Pecaric-Petkovic T., Groux-Keller M., et al. Invitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test. Clin Exp Allergy 2013, 43(9):1027-1037.
69. Porebski G., Gschwend-Zawodniak A., Pichler W.J. Invitro diagnosis of T cell-mediated drug allergy. Clin Exp Allergy 2011, 41(4):461-470.
70. Nassif A., Bensussan A., Dorothee G., et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. JInvest Dermatol 2002, 118(4):728-733.
71. Polak M.E., Belgi G., McGuire C., et al. Invitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol 2013, 168(3):539-549.
72. Beeler A., Zaccaria L., Kawabata T., et al. CD69 upregulation on T cells as an invitro marker for delayed-type drug hypersensitivity. Allergy 2008, 63(2):181-188.
73. Zawodniak A., Lochmatter P., Yerly D., et al. Invitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 2010, 65(3):376-384.
74. Fu M., Gao Y., Pan Y., et al. Recovered patients with Stevens-Johson syndrome and toxic epidermal necrolysis maintain long-lived IFN-gamma and sFasL memory response. PLoS One 2012, 7(9):e45516.
75. B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. Chem Res Toxicol 2013, 26(5):759-766.
76. Richter A., Schmucker S.S., Esser P.R., et al. Human T cell priming assay (hTCPA) for the identification of contact allergens based on naive T cells and DC-IFN-gamma and TNF-alpha readout. Toxicol InVitro 2013, 27(3):1180-1185.
77. Yawalkar N., Pichler W.J. Pathogenesis of drug-induced exanthema. Int Arch Allergy Immunol 2001, 124(1-3):336-338.
78. Yawalkar N., Shrikhande M., Hari Y., et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. JAllergy Clin Immunol 2000, 106(6):1171-1176.
79. Picard D., Janela B., Descamps V., et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010, 2(46):46ra62.
80. Schaerli P., Britschgi M., Keller M., et al. Characterization of human T cells that regulate neutrophilic skin inflammation. JImmunol 2004, 173(3):2151-2158.
81. Britschgi M., Steiner U.C., Schmid S., et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. JClin Invest 2001, 107(11):1433-1441.
82. Wei C.Y., Chung W.H., Huang H.W., et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. JAllergy Clin Immunol 2012, 129(6):1562-1569.e5.
83. Ko T.M., Chung W.H., Wei C.Y., et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. JAllergy Clin Immunol 2011, 128:1266-1276.e11.
84. Mennicke M., Zawodniak A., Keller M., et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant 2009, 9(9):2197-2202.
85. Maria V.A., Victorino R.M. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997, 41(4):534-540.